Innovating Works
HORIZON-JU-GH-EDCTP3-2024-Mpox
Mobilisation of Emergency funding for Mpox outbreak research resp...
Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health responders to the Mpox Public Health Emergency (PHE), as part of the efforts to manage and prevent the spread of the current epidemic. Proposals should result in new knowledge to manage and prevent future outbreaks and should strengthen the capacities of at-risk countries to respond to epidemics.
Sólo fondo perdido 0 €
European
This call is closed This line is already closed so you can't apply. It closed last day 29-05-2024.
Esta ayuda tiene otras 27 convocatoria(s) que puedes consultar.
Luckily, we have achieved the list of financed projects!
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health responders to the Mpox Public Health Emergency (PHE), as part of the efforts to manage and prevent the spread of the current epidemic. Proposals should result in new knowledge to manage and prevent future outbreaks and should strengthen the capacities of at-risk countries to respond to epidemics.

To that end, proposals submitted under this topic should aim at delivering results that are contributing to the following expected outcomes:

Provide novel, critical and timely insights into the Mpox outbreak and/or potential avenues for its management or prevention, focusing on the most affected population, specifically children, pregnant women and immunosuppressed individuals.Be timely, with rapid activation, to enable early and valuable outcomes and results to be produced and/or to support access time-dependent resources.To contribute to the public health preparedness and response in the context of the ongoing Mpox epidemic. Scope:The Global Health EDCTP3 Work Programme 2024 [1] foresees funding to be mobilised in case of a P... see more

Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health responders to the Mpox Public Health Emergency (PHE), as part of the efforts to manage and prevent the spread of the current epidemic. Proposals should result in new knowledge to manage and prevent future outbreaks and should strengthen the capacities of at-risk countries to respond to epidemics.

To that end, proposals submitted under this topic should aim at delivering results that are contributing to the following expected outcomes:

Provide novel, critical and timely insights into the Mpox outbreak and/or potential avenues for its management or prevention, focusing on the most affected population, specifically children, pregnant women and immunosuppressed individuals.Be timely, with rapid activation, to enable early and valuable outcomes and results to be produced and/or to support access time-dependent resources.To contribute to the public health preparedness and response in the context of the ongoing Mpox epidemic. Scope:The Global Health EDCTP3 Work Programme 2024 [1] foresees funding to be mobilised in case of a Public Health Emergency (PHE). This mechanism allows rapid mobilisation of research funding with or without a call for proposals in exceptional and duly substantiated emergencies. Global Health EDCTP3 considers a situation as an emergency if it is unforeseen and presents a serious and immediate risk to human health.

Following the Mpox outbreak in the Democratic Republic of Congo (DRC), first reported in 2023, the DRC Government, Africa CDC, World Health Organization (WHO) and partners have been closely monitoring it. From 1 January through 12 November 2023, a total of 12 569 suspected Mpox cases, including 581 suspected Mpox deaths (case fatality ratio: 4.6%), had been reported in 156 health zones from 22 out of 26 (85%) provinces of the DRC [2]. In 2024, and as of 29 March, 4 488 cases have been reported, of which 319 have been confirmed. A total of 279 deaths have been reported in the country in 2024 (CFR: 6.7%)[3].

On 13 April 2024, a High-Level Emergency Regional Meeting [4] was held in Kinshasa, to discuss the ongoing epidemic of Mpox in DRC and the potential risk of transmission to neighbouring countries and beyond. On the same day, the Ministry of Health (MoH) of DRC assessed the situation and considered the ongoing outbreak as a Public Health Emergency which requires a rapid and efficacious response. Aligning with this statement, the High-Level Meeting ended with a Communiqué (dated 13 April 2024) whereby twelve Ministers of Health and international partners called for a coordinated response to the outbreak and for the establishment of an Africa Taskforce for Mpox Coordination among Member States affected and at-risk of Mpox. These documents include a call to accelerate research and regulatory processes to enable access to vaccines, diagnostics and therapeutics for affected populations including children.

In the light of rising numbers of cases being reported in the DRC and the high public health risk, the Global Health EDCTP3 is activating the emergency funding mechanism to support research and innovation projects and activities as part of the Joint Undertaking’s response to the emergency.

The Global Health EDCTP3 invites proposals for Research & Innovation Actions (RIA) to support research activities in DRC and neighbouring or affected countries, to manage and/or prevent the spread of the current Mpox outbreak.

Proposals should address one or more of the following areas:

Vaccines research and development: Trials should focus on both pre-exposure prophylaxis and post-exposure prophylaxis.

Clinical trials for therapeutics: Proposals should include trials on therapeutic products in the context of the Monitored Emergency Use of Unregistered Interventions (MEURI), such as tecovirimat (approved by the European Medicines Agency for use in the European Union) and other promising therapeutic candidates. Research on pain management strategies should integrated in the proposed R&D efforts.

Surveillance strategies, evaluation of rapid diagnostics and epidemiological studies: Proposals should provide data on epidemiological characteristics such as geographical spread, viral genotype, and pathogenicity, clinical information on host susceptibility and host immune responses. This work is foreseen to use and evaluate available diagnostic tools to ensure improved surveillance.

Moreover, proposals should ensure:

Focus on the most affected population, specifically children, pregnant women and immunosuppressed individuals.Alignment with the national priorities of the DRC and neighbouring countries as well as the African Taskforce for Mpox Coordination.Partnership with researchers and public health institutions in DRC and neighbouring countries.Strengthening of national and local research capacity.Coordination and collaboration with other research and/or humanitarian activities operational in the countries affected.Alignment with the Africa CDC Task Force recommendations for rapid activation of R&D activities to control the outbreak.Compliance with International Council on Harmonisation – Good Clinical Practice (ICH-GCP), regulatory and ethical standards.Commitment to open access and data sharing principles, including appropriate data management and governance plans.Demonstrate alignment/synergy with DRC national government health service delivery policy and plans, where appropriate. Proposals should provide novel, critical and timely insights into the Mpox outbreak and/or potential avenues for its management or prevention, focusing on the most affected population, specifically children, pregnant women and immunosuppressed individuals.

Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established and/or to access time-dependent resources.

Proposals funded under this mechanism must share the relevant generated data within 30 days after generation with all parties that need and can use the findings to address the PHE.

[1] https://globalhealth-edctp3.eu/resources/work-programme-2024

[2] https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493

[3] https://www.ecdc.europa.eu/en/news-events/outbreak-mpox-caused-monkeypox-virus-clade-i-democratic-republic-congo

[4] https://www.afro.who.int/media-centre/statements-commentaries/united-fight-against-mpox-africa

see less

Temáticas Obligatorias del proyecto: Temática principal: Africa Clinical research Infectious diseases Preparedness Public health Societal Engagement International Cooperation Clinical trials Emerging Epidemics Social sciences and humanities Clinical Research Infectious Diseases Public Health Clinical Trials Social Sciences and Humanities Public Health Infectious Diseases

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño por participante: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health responders to the Mpox Public Health Emergency (PHE), as part of the efforts to manage and prevent the spread of the current epidemic. Proposals should result in new knowledge to manage and prevent future outbreaks and should strengthen the capacities of at-risk countries to respond to epidemics. Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health responders to the Mpox Public Health Emergency (PHE), as part of the efforts to manage and prevent the spread of the current epidemic. Proposals should result in new knowledge to manage and prevent future outbreaks and should strengthen the capacities of at-risk countries to respond to epidemics.
Do you want examples? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 4:. Los componentes que integran determinado proyecto de innovación han sido identificados y se busca establecer si dichos componentes individuales cuentan con las capacidades para actuar de manera integrada, funcionando conjuntamente en un sistema. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
For the eligible budget, the intensity of the aid in the form of a lost fund may reach as minimum a 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
deduction R&D+i:
0% 25% 50% 75% 100%
Ark + info
HORIZON-JU-GH-EDCTP3-2025-03-NETWORKS-01-two-stage Global collaboration action for strengthening the Regional Networks of Excellence and Epidemic Preparedness Consortia
en consorcio: Expected Impact:Expected impact The actions funded under this topic should contribute to increased international cooperation among research...
Próximamente
HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage Global Health EDCTP3 JU and contributing partners funded Strategic Training Hubs for Fellowships in Public Health covering Biostatistics, Epidemiology and Modelling
en consorcio: Expected Impact:Expected Impact The actions funded under this topic should contribute to increased international cooperation amongresearche...
Próximamente
HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa
en consorcio: Expected Impact:Expected impact The actions funded under this topic should contribute to increased international cooperation among research...
Próximamente
HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage Global collaboration action for research on existing Malaria therapeutics and clinical development of new antimalarial candidates
en consorcio: Expected Impact:Expected impact The action funded under this call for proposals should contribute to increased international cooperation am...
Próximamente
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage Accelerating the development of prophylactic vaccines against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
en consorcio: Expected Outcome:Background Neglected Tropical Diseases (NTDs) represent a challenge to public health, particularly in the African continen...
Próximamente
HORIZON-JU-GH-EDCTP3-2024-Mpox Mobilisation of Emergency funding for Mpox outbreak research response
en consorcio: Expected Outcome:This topic aims at supporting activities that contribute to answering the most pressing questions raised by public health r...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage New tools, technologies and approaches for vector control in sub-Saharan Africa
en consorcio: Expected Impact:Activities funded under the 2024 work programme of the Global Health EDCTP3 JU calls for proposals should contribute to: re...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-JU-GH-EDCTP3-2024-02-01-two-stage Global Health EDCTP3 JU training fellowship with return phase
en consorcio: Expected Impact:Expected Impacts Activities funded under the 2024 work programme of the Global Health EDCTP3 JU calls for proposals should...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage Innovative digital health solutions for sub-Saharan Africa
en consorcio: Expected Impact:Activities funded under the 2024 work programme of the Global Health EDCTP3 JU calls for proposals should contribute to: re...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
en consorcio: Expected Impact:Activities funded under the 2024 work programme of the Global Health EDCTP3 JU calls for proposals should contribute to: re...
Cerrada does 1 year | next call scheduled for the month of